Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma
NCT03004833Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Feb 2017
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in classical Hodgkin lymphoma (cHL), sponsored by University of Cologne. Started Feb 2017; status: completed.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03004833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03004833.